F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. It was founded in 2010 and headquartered in Cambridge, Massachusetts.

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Astrogen Co. Ltd. engages in the development of new drugs for intractable neurological diseases. The company was founded in July 2017 and is headquartered in Daegu, South Korea.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Levo Therapeutics is a biomedical research and development services intended to treat the multisystem neurodevelopmental disorder. The company's research and development services are dedicated to using genetic insights to advance treatments for Prader-Willi syndrome and related disorders, enabling patients to get cured of severe neurodevelopmental disorders.

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

A. Carlsson Research AB, part of NTG Nordic Transport Group A/S, is a Swedish company located in Gothenburg that develops and discovery and clinical development of new pharmacological treatment principles for psychiatric and neurological disorders. Arvid M. Carlsson is currently the CEO of the firm. NTG Nordic Transport Group An acquired A. Carlsson Research AB on October 23, 2006 for $121.91 million.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

Nobelpharma was founded in 2003, and in 2008 we obtained our first marketing approval for an ethical drug, NOBELZIN®. We now have marketing approvals for and sell 18 new drugs and one new medical device. In the pharmaceuticals industry, there are no companies of similar scale and age launching as many new drugs as we have. It is the pursuit of our unique product planning and research and development that has led to this achievement. We engage in the projects of "drugs and medical devices for unmet medical needs" which are critical but neglected. We chose not to carry out the time-consuming and costly basic researches. Instead, we conduct license negotiations and research activities focusing on patient needs and select the best possible candidates (new drug candidates) from outside our company. This is because we want to deliver the drugs and medical devices for unmet medical needs to the medical front as quickly as possible, for the benefit of the patients. Unique management strategy for

Institut du Cerveau et de la Moelle ��pini��re is a French private company located in Paris. The firm engages in spinal cord and brain research and educational services. It was founded by Maurice L��vy and Serge Weinberg.

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Bened Biomedical Co., Ltd. is a company headquartered in Taipei, Taiwan, with operations in the United States. The firm manufactures pharmaceuticals. It was founded in 2015 by Ying-Chieh Tsai. Frankie Cheng is the current CEO of the company.\nThe company says this about itself: Founded in 2015 in Taipei, Taiwan, Bened Biomedical Co., Ltd. is a global leader of microbiome-based products. The company focuses on therapy for neuropsychological, aging-related, allergic, immunological, and metabolic disorders. Bened aims to develop functional probiotic strains and live biotherapeutic products that can alter human microbiome to prevent and treat diseases. The name “Bened,” derived from the Latin word for “full of blessings,” affirms the brand's hope to bless the world through its products.

Undbio develops pharmaceuticals to treat diabetes, cancer, and immunology related diseases.

The European Institute of Oncology strives to achieve the excellence in the area of cancer prevention, early diagnosis and effective treatment through the development of clinical and scientific research and through organizational and managerial innovation, with a constant focus on the quality of the service provided to the patients. At the Institute, all the physicians work full time on an exclusive basis. In this way, doctors avoid dividing their time between hospital and private practice and dedicate all of their time to treatment, research, continuing professional education and interdisciplinary exchanges with their colleagues within the same facility to the benefit of their patients.

Woolsey Pharmaceuticals is a pharmaceutical company that specializes in reinventing ways to treat some of the world’s most challenging diseases. The company's approach allows them to accelerate the delivery of medicines for the benefit of all humankind. The company was founded in 2019 and is headquartered in New York, United States.